Alberta Research Innovation

Our Passion for Drug Discovery Research

ARCI’s mission is to improve human health and well being through the development of therapeutics to meet the 21st century’s pressing medical challenges. Leveraging our years of experience in the drug discovery research in oncology and small molecule therapeutics for the most prevalent diseases in the current world, we would like to develop novel products with strong intellectual property and become your partner of choice for your drug-development activities.

At ARCI,  we provide knowledge based drug discovery services to major pharmaceutical organizations and develop intellectual property in various therapeutic areas. We create discovery platforms with preliminary screening and the results are transferred to organizations under confidentiality agreements with 100% ownership to our clients. There is an increasing demand for new drug discovery and we intend to take advantage of this opportunity with our vast combined experience in small molecule drug discovery research.

Technology: Alberta Research Innovation is currently interested in the following therapeutic areas:

Cancer: As the cancer prevalence is increasing at an alarming rate, the demand for new cancer therapeutics has been growing considerably. Most number of drugs that have been approved by the FDA every year are still cancer therapeutics. Yet, as cancer research has been a daunting task, new targets have been continuously emerging and targeted therapies are taking precedence over the conventional non-specific cancer treatments. At ARCI, we have expertise in developing small molecule therapeutics for targeted therapies of cancers.

Infectious diseases: The increasing concern for resistance to the current antibiotics and very limited new approvals created great demand for the new treatments to infectious diseases. As a result, the market potential for antibiotics and anti-viral drugs is steeply rising. At ARCI, we have novel and innovative ideas to capture this alluring market.

Vaccine adjuvants: Vaccines continue to be an important public health tool in the control of infectious diseases, from small pox to current COVID-19!  Adjuvants are the critical components of vaccines because they induce specific immune responses that are more robust and long-lasting. Searching for promising adjuvants that are safe and improve the efficacy of the vaccines, to replace the currently used aluminum based adjuvants, has been very challenging.  At ARCI, we are developing various Toll-Like Receptor (TLR) ligands as novel vaccine adjuvants that provide more robust, specific and balanced immune responses.

We are currently seeking partners/out licensing opportunities in the areas of novel small molecule cancer therapeutics as well as novel vaccine adjuvants.